55863-28-0

Upstream product

• 64-17-5 ethanol 
• 39161-84-7 4-mercaptophenylacetic acid 

Downstream Products

• 866765-08-4 [4-(2-oxo-propylsulfanyl)-phenyl]-acetic acid ethyl ester 
• 866764-95-6 (4-ethoxymethylsulfanyl-phenyl)-acetic acid ethyl ester 
• 1046150-87-1 ethyl (4-cyclopentylsulfanylphenyl)acetate 
• 87202-52-6 (4-chlorosulfonyl-phenyl)acetic acid ethyl ester 
• 1105193-73-4 2-{4-[(1-methylethyl)sulfonyl]phenyl}acetic acid 
• 1328997-87-0 (2,4-difluoro-phenoxy)-[4-(piperidine-1-sulfonyl)-phenyl]-acetic acid ethyl ester 
• 1328997-86-9 bromo-[4-(piperidine-1-sulfonyl)-phenyl]-acetic acid ethyl ester 
• 1328997-85-8 bromo-(4-chlorosulfonyl-phenyl)-acetic acid ethyl ester 
• 1328997-88-1 (2,4-difluorophenoxy)-[4-(piperidine-1-sulfonyl)phenyl]acetic acid 

Relevant academic research and scientific papers

ROR GAMMA (RORY) MODULATORS

The present invention relates to compounds according to Formula I: Wherein: A11 - A14 are N or CR11, CR12, CR13, CR14, respectively, with the proviso that no more than two of the four positions A can be simultaneously N; R1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1 -3)alkyl)amino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl; R2 and R3 are independently H, F, methyl, ethyl, hydroxy, methoxy or R2 and R3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F; R4 is H or C(1-6)alkyl; R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1 -9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano; the sulfonyl group with R1 is represented by one of R7, R8 or R9; the remaining R6-RH are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F; and Ri5 and Ri6 are independently H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.

Acetamide compounds as glucokinase activators, their process and medicinal applications

Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or m

AUTOTAXIN INHIBITORS AND USES THEREOF

Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION

Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or m

6,11-Dihydro-11-oxo-dibenzo[b,e]thiepine-2-acetic acids

The present invention provides compounds of formula I, SPC1 wherein R1 is hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl, lower alkoxy, amino or lower acylamino, and R2 is hydrogen or lower alkyl, Useful as antiphlogist